Cited by 377SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Open access

Ali, Kashif, Berman, Gary, Zhou, Honghong, Deng, Weiping, Faughnan, Veronica, Coronado-Voges, Maria, Ding, Baoyu, Dooley, Jacqueline, Girard, Bethany, Hillebrand, William, Pajon, Rolando, Miller, Jacqueline M., Leav, Brett, McPhee, Roderick·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2109522PMC PMC8385554

Open this paper in CoChat — free account

Abstract

BACKGROUND: The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. METHODS: In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. CONCLUSIONS: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2109522

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,774
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Family violence and COVID‐19: Increased vulnerability and reduced options for support
Usher, K., Bhullar, N., Durkin, J., Gyamfi, N., & Jackson, D. (2020) · International Journal of Mental Health Nursing · doi:10.1111/inm.12735 · Cited by 979
Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults
Viner, R., Mytton, O. T., Bonell, C. P., Meléndez‐Torres, G. J., Ward, J., Hudson, L. D., Waddington, C. S., Thomas, J., Russell, S., van der Klis, F. R. M., et al. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.4573 · Cited by 893
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673
Self-citation
Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020
Kim, L., WHITAKER, M. D., O’Halloran, A. C., Kambhampati, A. K., Chai, S. J., Reingold, A. L., Armistead, I., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 1

10.1056/NEJMoa2027906 · DOI · Paper page

Sorted by citations

Items 101–200 of 374

An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
Okada, M., Kikuchi, E., Nagasawa, M., Oshiba, A., & Shimoda, M. (2022) · CEN Case Reports · doi:10.1007/s13730-021-00679-7 · Cited by 17
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Children with a History of Multisystem Inflammatory Syndrome in Children: An International Survey
Hoste, L., Soriano‐Arandes, A., Buddingh, E. P., Whittaker, E., Bélot, A., Ulloa‐Gutiérrez, R., Olbrich, P., & Haerynck, F. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.05.028 · Cited by 18
Vaccine formulation design: challenges and opportunities
Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 17
Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy
Akelew, Y., Henok, A., Ebrahim, E., Atnaf, A., & Hailemichael, W. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.573 · Cited by 17
Reasons in favour of universal vaccination campaign against COVID-19 in the pediatric population
Principi, N., & Esposito, S. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-021-01192-4 · Cited by 16
Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine
Hill, J., Montross, D., & Ivarsson, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1113003 · Cited by 16
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
Ильдарович, Т. А., Dolzhikova, I. V., Dzharullaeva, A. S., Grousova, D. M., Витальевна, К. А., Zubkova, O. V., Zorkov, I. D., Iliukhina, A. A., Shelkov, A. Y., Erokhova, A. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228461 · Cited by 16
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Joshi, K., Scholz, S. M., Maschio, M., Kohli, M. A., Lee, A., Fust, K., Ultsch, B., de Velde, N. V., & Beck, E. C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2290388 · Cited by 16
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children
Chow, E. J., & Englund, J. A. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.005 · Cited by 21
mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
Comprehensive antibody profiling of mRNA vaccination in childrenPreprint
Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.07.463592 · Cited by 16
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.030 · Cited by 17
Association between COVID-19 vaccines and the menstrual cycle in young Japanese women
Kajiwara, S., Akiyama, N., Baba, H., & Ohta, M. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.01.003 · Cited by 15
Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden
Nordström, P., Ballin, M., & Nordström, A. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004127 · Cited by 15
Immune responses to SARS-CoV-2 infection and vaccination in children
Brodin, P. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101794 · Cited by 17
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 16
BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
Rudan, I., Millington, T., Antal, K., Grange, Z., Fenton, L., Sullivan, C. B., Buelo, A., Wood, R., Woolford, L., Swann, O. V., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100513 · Cited by 15
Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19
Nehab, M. F., Camacho, K. G., Reis, A. T., Junqueira-Marinho, M. D. F., Abramov, D. M., de Azevedo, Z. M. A., Salú, M. D. S., de Vasconcelos, Z. F. M., Gomes, S. C., Filho, O. C. D. S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.077 · Cited by 17
Calendario de vacunaciones de la Asociación Española de Pediatría: Recomendaciones 2022
García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Llanos, E. G., de Arce, A. I., Melián, A. M., Gómez, M. L. N., Solas, V. P., Calle, I. R., et al. (2022) · Anales de Pediatría · doi:10.1016/j.anpedi.2021.11.003 · Cited by 15
Serious harms of the COVID-19 vaccines: a systematic reviewPreprint
Gøtzsche, P. C., & Demasi, M. (2022) · medRxiv · doi:10.1101/2022.12.06.22283145 · Cited by 17
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Alexopoulos, H., Trougakos, I., Dimopoulos, M., & Terpos, E. (2022) · European journal of internal medicine · doi:10.1016/j.ejim.2022.11.009 · Cited by 14
Parental refusal and hesitancy of vaccinating children against COVID-19: Findings from a nationally representative sample of parents in the U.S.
Panchalingam, T., & Shi, Y. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107288 · Cited by 15
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
Liu, L. T.-C., Chiu, C., Chiu, N., Tan, B., Lin, C., Cheng, H., Lin, M., Lien, C.-E., Chen, C., & Huang, L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00589-4 · Cited by 16
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials
Ahmadizar, F., Luxi, N., Raethke, M., Schmikli, S. L., Riefolo, F., Saraswati, P. W., Bucșa, C., Osman, A. K., Liddiard, M., Batel-Marques, F., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01304-5 · Cited by 15
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Shabu, A., & Nishtala, P. S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2209177 · Cited by 15
BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Fang, S.-F., Liu, N., & Du, H. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2118775 · Cited by 15
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 14
Vaccination against COVID-19 — risks and benefits in children
Munro, A. P. S., Jones, C. E., & Faust, S. N. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-023-05380-8 · Cited by 18
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Dechates, B., Harnphadungkit, M., Sornsamdang, G., Wittayasak, K., Soonklang, K., & Mahanonda, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2035573 · Cited by 13
Vaccination of children against COVID-19: the experience in Latin America
Rodriguez-Morales, A. J., León‐Figueroa, D. A., Romaní, L., McHugh, T. D., & Leblebicioğlu, H. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00505-7 · Cited by 16
COVID-19 vaccination in children: a public health priority
Lima, E. J. D. F., & Leite, R. D. (2022) · Jornal de Pediatria · doi:10.1016/j.jped.2022.11.006 · Cited by 14
Explore the attitudes of children and adolescent parents towards the vaccination of COVID-19 in China
Wang, L., Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhang, X., Wang, M., Feng, Z., et al. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01321-7 · Cited by 12
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India
Gunale, B., Kapse, D., Kar, S., Bavdekar, A., Kohli, S., Lalwani, S. K., Meshram, S., Raut, A. V., Kulkarni, P., Samuel, C., et al. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.2552 · Cited by 12
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Seguridad de las vacunas contra la COVID-19
Chaparro-Mérida, N. A., Samper, D. M., & Lacato, A. O. F. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9308 · Cited by 15
Unvaccinated Children Are an Important Link in the Transmission of SARS-CoV-2 Delta Variant (B1.617.2): Comparative Clinical Evidence From a Recent Community Surge
Li, H., Lin, H., Chen, X., Li, H., Li, H., Lin, S., Huang, L., Chen, G., Zheng, G., Wang, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.814782 · Cited by 13
An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement
Rocha, V. P. C., Quadros, H. C., Fernandes, A. M. S., Gonçalves, L. P., Badaró, R. J. D. S., Soares, M. B. P., & Machado, B. A. S. (2023) · Viruses · doi:10.3390/v15071504 · Cited by 13
Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
Nziza, N., Deng, Y., Wood, L., Dhanoa, N., Dulit-Greenberg, N., Chen, T., Kane, A. S., Swank, Z., Davis, J. P., Demokritou, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45181-7 · Cited by 13
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
Lawson‐Tovey, S., Machado, P., Strangfeld, A., Mateus, E. F., Gossec, L., Carmona, L., Raffeiner, B., Buliņa, I., Clemente, D., Zepa, J., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002322 · Cited by 12
A systematic review of current status and challenges of vaccinating children against SARS-CoV-2
Zhang, M., Zhang, P., Liang, Y., Du, B., Li, L., Yu, Z., Wang, H., Wang, Q., Zhang, X., & Zhang, W. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.006 · Cited by 11
Guardians’ willingness to vaccinate their teenagers against COVID-19 in China: A national cross-sectional survey
Wu, J., Zhao, L., Wang, M., Gu, J., Wei, W., Li, Q., Ma, M., Mu, Z., & Miao, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.002 · Cited by 11
Immunization schedule of the Pediatric Spanish Association: 2022 recommendations
García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Llanos, E. G., de Arce, A. I., Melián, A. M., Gómez, M. L. N., Solas, V. P., Calle, I. R., et al. (2022) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2021.11.002 · Cited by 11
Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices
Kasi, S. G., Dhir, S. K., Shah, A., Shivananda, S., Verma, S., Marathe, S. M., Chatterjee, K., Agarwalla, S. K., Srirampur, S., Kalyani, S., et al. (2021) · Indian Pediatrics · doi:10.1007/s13312-022-2421-9 · Cited by 11
Vaccines and nephrotic syndrome: efficacy and safety
Angeletti, A., Lugani, F., Porta, E. L., Verrina, E. E., Caridi, G., & Ghiggeri, G. M. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05835-4 · Cited by 13
Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis
Tian, Y., Chen, L., & Shi, Y. (2022) · Vaccines · doi:10.3390/vaccines11010087 · Cited by 11
Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
Katoto, P. D., Tamuzi, J. L., Brand, A., Marangu, D., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2214495 · Cited by 13
Intention to Vaccinate against COVID-19 in Adolescents: A Systematic Review
Tan, S. Y., Oka, P., & Tan, N. C. (2023) · Vaccines · doi:10.3390/vaccines11081393 · Cited by 12
Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China
Lu, C.-L., Zheng, R.-X., Xue, X., Zhang, X. W., Liu, X., Jin, X.-Y., Pu, F., Lan, H.-D., Fang, M., Kong, L., et al. (2021) · Integrative Medicine Research · doi:10.1016/j.imr.2021.100798 · Cited by 12
Infancia y COVID-19: Los efectos indirectos de la pandemia COVID-19 en el bienestar de niños, niñas y adolescentes
Díaz, F., & Fuentes, A. D. (2022) · Andes pediatrica · doi:10.32641/andespediatr.v93i1.4250 · Cited by 11
Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 13
COVID‐19 vaccines and their underbelly: Are we going the right way?
Satapathy, B. S., Pattnaik, G., Sahoo, R. N., Pattanaik, S., Sarangi, A. K., Kandi, V., Mishra, S., Rabaan, A. A., Mohanty, A., Sah, R., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1540 · Cited by 10
A review of COVID vaccines: success against a moving target
Chong, S. H., Burn, L., Cheng, M. T. K., Warr, I. S., & Kenyon, J. C. (2022) · British Medical Bulletin · doi:10.1093/bmb/ldac025 · Cited by 9
COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review
FERGIE, J. E., Moran, M. M., Cane, A. D., Pather, S., Türeci, Ö., & Srivastava, A. K. (2022) · Vaccines · doi:10.3390/vaccines10122039 · Cited by 10
Self-reported side effects following COVID-19 vaccination in athletes: A retrospective study
Komici, K., Verderosa, S., D’Amico, F., & Guerra, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2234788 · Cited by 10
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis
Costa, C., & Moniati, F. (2024) · Advances in Medicine · doi:10.1155/2024/4470326 · Cited by 10
Second Wave of the Study of Taiwanese Caregivers of Children with ADHD in the COVID-19 Pandemic: Intentions to Vaccinate Their Children for COVID-19, and Related Factors
Tsai, C., Wang, L., Hsiao, R. C.-J., & Yen, C. (2022) · Vaccines · doi:10.3390/vaccines10050753 · Cited by 10
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialPreprint
Áñez, G., Dunkle, L. M., Gay, C. L., Kotloff, K. L., Adelglass, J. M., Essink, B. J., Campbell, J. D., Cloney-Clark, S., Zhu, M., Plested, J. S., et al. (2022) · medRxiv · doi:10.1101/2022.09.20.22279903 · Cited by 10
Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12–17 years
Guo, B., Li, H.-B., & Yang, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.049 · Cited by 9
COVID-19 Vaccine Effectiveness Among Adolescents
Poukka, E., Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Perälä, J., Kristoffersen, A. B., Meijerink, H., Starrfelt, J., Ljung, R., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2023-062520 · Cited by 9
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years
Chu, K., Quan, J., Liu, X., Chen, Q., Zang, X., Jiang, H.-M., Liu, D., Chu, X., Zhuang, C., Han, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01096-y · Cited by 9
Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1)
Yahyaei, S., Abdoli, A., Jamali, A., Teimoori, A., Arefian, E., Eftekhari, Z., & Jamur, P. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70093 · Cited by 9
Consensus on COVID-19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology
Cesaro, S., Muggeo, P., Zama, D., Cellini, M., Perruccio, K., Colombini, A., Carraro, F., Petris, M. G., Petroni, V., Mascarin, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051235 · Cited by 8
Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months
Amodio, E., Genovese, D., Mazzeo, L., Martino, L., Restivo, V., Vella, G., Calamusa, G., & Vitale, F. M. (2022) · PEDIATRICS · doi:10.1542/peds.2022-057394 · Cited by 9
Lipid nanoparticle-encapsulated, chemically modified anti-adenoviral siRNAs inhibit hepatic adenovirus infection in immunosuppressed Syrian hamsters
Geisler, A., Dieringer, B., Elsner, L., Klingel, K., Klopfleisch, R., Vornlocher, H., Kurreck, J., & Fechner, H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.016 · Cited by 9
Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase
Kim, D. H., Kim, J. H., Oh, I., Choe, Y. J., Choe, S., & Shin, J. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e76 · Cited by 9
Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study
Chen, C., Chen, C., Cao, L., Fang, J., & Xiao, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112022 · Cited by 10
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
England, R. N., Drapeau, E. M., Alameh, M., Hosseinzadeh, R., Weissman, D., & Hensley, S. E. (2024) · npj Vaccines · doi:10.1038/s41541-024-00901-4 · Cited by 11
Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial
Figueroa, A. L., Ali, K., Berman, G., Zhou, H., Deng, W., Xu, W., Lussier, S. J., Girard, B., Dutko, F. J., Slobod, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102720 · Cited by 8
Self-citation
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
SARS-CoV-2 vaccines in children and adolescents: Can immunization prevent hospitalization?
Liang, K., Hung, K.-F., Wang, M., Chang, T.-J., Cheng, Y., Chiang, S., Chen, M., Liao, Y.-T., Chiou, S., & Yang, D. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000774 · Cited by 9
Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in children
Ruedas-López, A., Berzosa, A., Illán-Ramos, M., Caballero, I. C., Guillén-Martín, S., Bodas-Pinedo, A., Rueda-Esteban, S., Pérez‐Rodríguez, O., López, R. V., Lara, D. L., et al. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127145 · Cited by 9
Vaccinating Children against SARS-CoV-2: A Literature Review and Survey of International Experts to Assess Safety, Efficacy and Perceptions of Vaccine Use in Children
Hookham, L., Lee, H. C., Patel, D. A., Coelho, M., Giglio, N., Doaré, K. L., & Pannaraj, P. S. (2022) · Vaccines · doi:10.3390/vaccines11010078 · Cited by 9
COVID-19 Vaccines in Children
Fayad, D., & Frenck, R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010087 · Cited by 11
Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights
O’Reilly, S. R., Byrne, J., Feeney, E. R., Mallon, P. W. G., & Gautier, V. (2024) · Vaccines · doi:10.3390/vaccines12101089 · Cited by 8
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS
Mercolini, F., & Cesaro, S. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.009 · Cited by 9
Considerations for vaccinating children against COVID-19
Hart, J., Ong, D. S., Chokephaibulkit, K., Ong-Lim, A., Vereti, I., Crawford, N. W., & Russell, F. M. (2023) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2023-001964 · Cited by 8
Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
Shabu, A., & Nishtala, P. S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2260477 · Cited by 8
Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea
Choe, Y. J., Ahn, Y.-H., Gwak, E. S., Jo, E., Kim, J., & Choe, S. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06195-3 · Cited by 8
A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study
Fedele, G., Schiavoni, I., Trentini, F., Leone, P., Olivetta, E., Fallucca, A., Fiore, S., Martino, A. D., Abrignani, S., Baldo, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272119 · Cited by 7
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
Priddy, F. H., Chalkias, S., Essink, B. J., Whatley, J. L., Brosz, A. B., Lee, I. T., Feng, J., Tracy, L. A., Deng, W., Zhou, W., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2397026 · Cited by 8
Self-citation
Recommendations for the urgent need to vaccinate school-aged and adolescent children against COVID-19 in the Asia–Pacific region
Kobayashi, J., Takeuchi, R., Shibuya, F., Murata, Y., & Takahashi, K. (2021) · Tropical Medicine and Health · doi:10.1186/s41182-021-00365-5 · Cited by 8
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Vanichsetakul, P., Thonginnetra, S., Niemsorn, K., Promsena, P., Tandhansakul, M., Kasemlawan, N., Ruangkijpaisal, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10050807 · Cited by 8
Protecting Children Against Omicron
Katz, S. E., & Edwards, K. M. (2022) · JAMA · doi:10.1001/jama.2022.7315 · Cited by 7
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
Leav, B. A., Straus, W. L., White, P., Leav, A., Gaines, T., Maggiacomo, G., Kim, D., Smith, E. R., Gurwith, M., & Chen, R. T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.005 · Cited by 9
Self-citation
Dilemmas and options for COVID-19 vaccination in children
Wen, J., Du, X., Li, A., Zhang, S., Shen, S., Zhang, Z., Yang, L., Sun, C., Li, J., & Zhu, S. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01513-9 · Cited by 10
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 9
Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study
Wang, T., Li, C., Li, H., & Li, Z. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057281 · Cited by 8
An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in ChilePreprint
Soto, J. A., Melo-González, F., Gutiérrez-Vera, C., Schultz, B. M., Berríos-Rojas, R. V., Rivera-Pérez, D., Piña-Iturbe, A., Hoppe-Elsholz, G., Duarte, L. F., Vázquez, Y., et al. (2022) · medRxiv · doi:10.1101/2022.02.15.22270973 · Cited by 7
A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database
Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11
Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2
Schreiner, T., Wilson-Murphy, M., Mendelt-Tillema, J., Waltz, M., Codden, R. R., Benson, L., Gorman, M., Goyal, M. S., Krupp, L., Lotze, T., et al. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231151948 · Cited by 7
The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement
Bellavite, P., Donzelli, A., & Isidoro, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237291 · Cited by 7
EVALUATION COMPARISON BETWEEN ASTRAZENECA AND MODERNA VACCINE’S SIDE EFFECTS AND EFFICACY AMONG INDONESIA SOCIETY BASED ON SOCIODEMOGRAPHY
Araminda, G. N., & Ramatillah, D. L. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s2.44747 · Cited by 7
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials
Siangphoe, U., Baden, L. R., Sahly, H. M. E., Essink, B. J., Ali, K., Berman, G., Tomassini, J. E., Deng, W., Pajón, R., McPhee, R. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac780 · Cited by 7
Self-citation
Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review
Wu, H. H. L., Shenoy, M. A., Kalra, P. A., & Chinnadurai, R. (2022) · Children · doi:10.3390/children9101467 · Cited by 7
COVID-19 Vaccination in Young People with Functional Neurological Disorder: A Case-Control Study
Lim, N., Wood, N., Prasad, A., Waters, K. A., Singh‐Grewal, D., Dale, R. C., Elkadi, J., Scher, S., & Kozlowska, K. (2022) · Vaccines · doi:10.3390/vaccines10122031 · Cited by 8
COVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non–vaccine-associated myocarditis within the prospective multicenter registry—“MYKKE”
Rolfs, N., Huber, C., Schwarzkopf, E., Mentzer, D., Keller‐Stanislawski, B., Opgen‐Rhein, B., Frede, W., Rentzsch, A., Hecht, T., Boehne, M., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.11.006 · Cited by 9
mRNA vaccines for prostate cancer: A novel promising immunotherapy
Tang, Y., Yi, X., & Ai, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189333 · Cited by 6
Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19
Liu, Z., Han, Z., Jin, X., An, J., Kim, J., Chen, W., Kim, J. S., Zheng, J., & Deng, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.010 · Cited by 6
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
Dixit, A., Bennett, R., Ali, K., Griffin, C., Clifford, R. A., Turner, M. A., Poston, R., Hautzinger, K., Yeakey, A. M., Girard, B., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00101-4 · Cited by 9
Self-citation

Authors: Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R.
Affiliations: From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).
Corresponding author: McPhee, Roderick
ORCID: Girard, Bethany
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-12-09
Volume: 385
Issue: 24
Pages: 2241-2251
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2109522
PMC: PMC8385554
OpenAlex: W3189261358
Cited by: 377
References: 20
Citations by year: 2026: 12 · 2025: 29 · 2024: 54 · 2023: 87 · 2022: 160 · 2021: 35
FWCI: 26.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, adolescents, vaccine safety, immunogenicity, neutralizing antibodies, non-inferiority, vaccine efficacy, asymptomatic infection, adverse events, serological response, pseudovirus neutralization assay, Omicron variant, Omicron BA.1
MeSH terms: Immunogenicity, Vaccine, COVID-19, Vaccine Efficacy, 2019-nCoV Vaccine mRNA-1273, Adolescent, Antibodies, Viral, Child, Female, Humans, Male, Single-Blind Method, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks